Volume | 401,381 |
|
|||||
News | - | ||||||
Day High | 11.00 | Low High |
|||||
Day Low | 10.1201 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Inovio Pharmaceuticals Inc New | INO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.00 | 10.1201 | 11.00 | 10.20 | 11.07 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,737 | 401,381 | $ 10.47 | $ 4,200,491 | - | 3.888 - 14.748 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:17:04 | 1 | $ 10.16 | USD |
Inovio Pharmaceuticals (INO) Options Flow Summary
Inovio Pharmaceuticals Inc New Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
238.38M | 23.37M | - | 832k | -135.12M | -5.78 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Inovio Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.61 | 11.96 | 8.35 | 10.63 | 437,182 | -1.41 | -12.14% |
1 Month | 10.89 | 14.748 | 8.35 | 11.97 | 459,325 | -0.69 | -6.34% |
3 Months | 6.92 | 14.748 | 4.73 | 9.57 | 504,493 | 3.28 | 47.40% |
6 Months | 5.772 | 14.748 | 3.888 | 7.09 | 2,146,664 | 4.43 | 76.72% |
1 Year | 11.46 | 14.748 | 3.888 | 6.68 | 4,275,024 | -1.26 | -10.99% |
3 Years | 104.2524 | 123.96 | 3.888 | 36.55 | 5,035,064 | -94.05 | -90.22% |
5 Years | 45.00 | 426.00 | 3.888 | 121.96 | 9,195,923 | -34.80 | -77.33% |
Inovio Pharmaceuticals Description
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. |